Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Study on the Construction and Implementation Effect of a Traditional Chinese Medicine-Based Mental-Physical Comorbidity Linked Health-Management System of "Hospital-Community-Family" for Breast Cancer Patients

In this study, the effect-implementation mixed research design was adopted. The patients were assigned to the intervention group and the control group at a ratio of 2 : 1 by the central stratified randomization method. The stratification factors were four phenotypes of psychosomatic symptoms ( anxiety and depression, sleep disorders, fatigue and mixed symptoms ). The intervention group was determined by the three-stage conversation model of doctor-patient joint decision-making, and the personalized acupuncture intervention program was determined. Combined with the patient 's own needs and service accessibility, the hospital intervention subgroup or the medical-social-home intervention subgroup scenario was determined. The control group was given routine nursing. Because the intervention requires informed interaction between doctors and patients, only outcome evaluators and data analysts are blinded. The intervention period was 8 weeks of treatment and 4 weeks of follow-up, a total of 12 weeks. Based on the evaluation of the effect of acupuncture intervention on the improvement of psychosomatic symptoms, the study was guided by the CFIR framework to evaluate the implementation of the hospital intervention subgroup and the medical-social-family intervention subgroup formed after the joint decision-making of doctors and patients, identify the implementation obstacles and promotion factors, and evaluate the implementation outcomes such as acceptability, feasibility, implementation loyalty and coverage.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

216

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Tianjin, Kina
        • First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

  1. Female, aged 18-70 years

  2. Histologically or cytologically confirmed breast cancer (AJCC 8th Edition Stage 0-IV)

  3. At least one psychosomatic symptom meeting the following criteria:

    • Anxiety or depression: Hospital Anxiety and Depression Scale (HADS) anxiety or depression subscale ≥ 8
    • Sleep disorder: Pittsburgh Sleep Quality Index (PSQI) total score ≥ 8
    • Cancer-related fatigue: Brief Fatigue Inventory (BFI) total score ≥ 4
  4. Expected survival ≥ 1 year

  5. Alert, conscious, with basic communication ability, able to complete questionnaire assessments

  6. Signed informed consent by patient or legal guardian

Exclusion Criteria:

  1. Severe mental disorders (e.g., schizophrenia, bipolar disorder) or lack of civil capacity
  2. Unsuitable for auricular acupressure: local auricular skin damage/infection/allergy to Vaccaria seeds or tape
  3. Currently receiving other acupuncture/acupressure interventions, or unable to discontinue during the study period
  4. Unsuitable for acupuncture: bleeding tendency (e.g., coagulopathy, purpura), or local acupoint damage
  5. Severe cardiac, hepatic, or renal failure, or cachexia
  6. Pregnant or breastfeeding women

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Sundhedstjenesteforskning
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Eksperimentel: Intervention Group

Participants receive personalized acupuncture intervention (acupuncture and/or auricular acupressure) determined through the Shared Decision Making three-stage conversation model, on top of standard care. Patients choose either hospital-based or hospital-community-family intervention sub-group based on personal needs and service accessibility. Treatment duration: 8 weeks intervention + 4 weeks follow-up.

Ingen indgriben: Control Group

Participants receive standard care only, including diet, exercise, emotional regulation guidance, and health education based on the Breast Cancer Psychosomatic Health Education Manual. No active acupuncture intervention for psychosomatic symptoms during the study period.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Functional Assessment of Cancer Therapy-Breast, FACT-B
Tidsramme: 8 weeks

Instruments for assessing Quality of Life (QoL) among breast cancer patients;Functional Assessment of Cancer Therapy-Breast (FACT-B Version 4.0) Uniform response options: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much Unified scoring rule for all subscales and total scores: Higher scores indicate better quality of life among breast cancer patients; lower scores reflect more severe physical, emotional, social and breast-specific distress.

8 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Hospital anxiety and depression scale,HADS
Tidsramme: 8 weeks

Hospital Anxiety and Depression Scale (HADS) Full Scoring Standard Specifications Subscale 1: Anxiety subscale (HADS-A) Number of items: 7 Minimum score: 0 Maximum score: 21 Interpretation: Higher scores mean more severe anxiety symptoms. Subscale 2: Depression subscale (HADS-D) Number of items: 7 Minimum score: 0 Maximum score: 21 Interpretation: Higher scores mean more severe depressive symptoms. HADS total score Composition: HADS-A score + HADS-D score Minimum score: 0 Maximum score: 42 Interpretation: Higher total scores indicate more severe combined anxiety and depression symptoms.

Supplementary Response Option Rule (Standard HADS 4-point Likert) All items adopt 4-point scoring from 0 to 3; higher single item scores stand for worse emotional conditions.

8 weeks
Pittsburgh sleep quality index,PSQI
Tidsramme: 8 weeks

Pittsburgh Sleep Quality Index (PSQI) Full Scoring Standard Description PSQI component subscores (7 sleep dimensions) Each component score range: 0-3 PSQI global total score Full name: Pittsburgh Sleep Quality Index Global Score Minimum score: 0 Maximum score: 21 Interpretation: Higher global scores represent worse overall sleep quality; lower scores indicate better sleep quality.

8 weeks
Brief Fatigue Inventory,BFI
Tidsramme: 8 weeks

Brief Fatigue Inventory (BFI) Full Scoring Standard Description Single item scoring range for each fatigue item: 0-10 BFI Global Fatigue Severity Score Full name: Brief Fatigue Inventory Global Fatigue Severity Score Minimum score: 0 Maximum score: 10 Interpretation: Higher scores indicate more severe fatigue; lower scores represent milder fatigue status.

Supplement The total global score is the average of all 9 items of the BFI. Each item uses a 0-10 numerical rating scale, where 0 = no fatigue at all and 10 = worst fatigue imaginable.

8 weeks
Brief Pain Inventory,BPI
Tidsramme: 8 weeks

Brief Pain Inventory (BPI) Full Scoring Standard Description Single item scoring range: Each pain-related item is scored on a 0-10 numeric rating scale (0 = no pain, 10 = worst pain imaginable) BPI Pain Severity Score Full name: Brief Pain Inventory Pain Severity Score Composition: Average score of 4 pain severity items (worst pain, least pain, average pain, pain right now) Minimum score: 0 Maximum score: 10 Interpretation: Higher scores mean greater pain severity BPI Pain Interference Score Full name: Brief Pain Inventory Pain Interference Score Composition: Average score of 7 pain interference items (interference with general activity, mood, walking ability, normal work, relations with others, sleep, enjoyment of life) Minimum score: 0 Maximum score: 10 Interpretation: Higher scores indicate more severe interference of pain on daily life

8 weeks

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Acceptability of the intervention
Tidsramme: 8 weeks

Acceptability of the intervention is assessed using a 4-item, 5-point Likert scale. Each item is scored from 1 to 5. The total score is calculated as the sum of the four item scores, ranging from 4 to 20. Higher scores indicate greater acceptability. A total score of ≥16 indicates good acceptability.

8 weeks
Feasibility of the intervention
Tidsramme: 8 weeks

Feasibility of the intervention is assessed using a 4-item, 5-point Likert scale. Each item is scored from 1 to 5. The total score is calculated as the sum of the four item scores, ranging from 4 to 20. Higher scores indicate greater feasibility. A total score of ≥16 indicates good feasibility.

8 weeks
Implementation Fidelity: Auricular Acupressure Treatment Adherence Rate
Tidsramme: 8 weeks

Auricular acupressure treatment adherence rate = (Number of auricular acupressure sessions actually completed / Number of required sessions) × 100%. An adherence rate of ≥80% indicates good adherence.

8 weeks
Implementation Fidelity: Self-Pressing Adherence Rate
Tidsramme: 8 weeks

Self-pressing adherence was assessed by recording the daily frequency of self-pressing in patient logs and verifying the records by asking participants during follow-up visits. An adherence rate of ≥90% indicates good adherence.

8 weeks
Coverage of the intervention
Tidsramme: 8 weeks

Coverage was defined as the proportion of eligible breast cancer patients with psychosomatic symptoms who participated in the study.

8 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

30. oktober 2026

Primær færdiggørelse (Anslået)

31. december 2028

Studieafslutning (Anslået)

31. december 2028

Datoer for studieregistrering

Først indsendt

18. oktober 2026

Først indsendt, der opfyldte QC-kriterier

11. november 2026

Først opslået (Faktiske)

17. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 25ZXWQSY00040

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .